^
    Back
    Association details:
    Biomarker:PTPN12 deletion
    Cancer:Triple Negative Breast Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    sunitinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nat Med
    Title:

    Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer

    Excerpt:
    Notably, in the PTPN12-deficient TNBC models PDX-1 and PDX-2, Crizotinib-Sunitinib treatment led to complete tumor regression, in contrast with the single-agent treatments…
    DOI:
    10.1038/nm.4507